Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Allogene Therapeutics Inc
(NQ:
ALLO
)
2.770
-0.240 (-7.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
January 03, 2023
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product.
Via
Investor's Business Daily
Top 10 Highest Short Interest Stocks And 10 With Highest Cost To Borrow: Where Do Carvana, MicroStrategy, Fisker And AMC Rank?
December 17, 2022
Investors often look for stocks with high short interest and a high cost to borrow, which could predict a potential short squeeze. New data shared by S3 Partners could signal which stocks investors are...
Via
Benzinga
Expert Ratings for Allogene Therapeutics
September 22, 2022
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings:
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
December 12, 2022
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
December 12, 2022
Via
Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
November 29, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
November 09, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
November 03, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
November 02, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
October 31, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
October 26, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
October 11, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
October 06, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
September 22, 2022
Gainers
Via
Benzinga
Apple, Amazon, HP And Other Big Losers From Friday
August 29, 2022
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
August 29, 2022
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Via
Benzinga
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
August 10, 2022
Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
August 10, 2022
Via
Benzinga
Allogene Therapeutics: Q2 Earnings Insights
August 09, 2022
Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
July 20, 2022
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
July 15, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 15, 2022
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
June 03, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Allogene Therapeutics
June 03, 2022
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.